125 related articles for article (PubMed ID: 25082095)
1. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy.
Mulvihill DJ; McMichael K; Goyal S; Drachtman R; Weiss A; Khan AJ
Radiother Oncol; 2014 Aug; 112(2):279-83. PubMed ID: 25082095
[TBL] [Abstract][Full Text] [Related]
2. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy.
Campbell BA; Hornby C; Cunninghame J; Burns M; MacManus M; Ryan G; Lau E; Seymour JF; Wirth A
Ann Oncol; 2012 May; 23(5):1259-1266. PubMed ID: 21980193
[TBL] [Abstract][Full Text] [Related]
3. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
[TBL] [Abstract][Full Text] [Related]
4. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study.
Weber DC; Peguret N; Dipasquale G; Cozzi L
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1578-86. PubMed ID: 19596171
[TBL] [Abstract][Full Text] [Related]
5. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
[TBL] [Abstract][Full Text] [Related]
6. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
Maraldo MV; Jørgensen M; Brodin NP; Aznar MC; Vogelius IR; Petersen PM; Berthelsen AK; Christensen CB; Hjalgrim LL; Specht L
Pediatr Blood Cancer; 2014 Apr; 61(4):717-22. PubMed ID: 24660228
[TBL] [Abstract][Full Text] [Related]
7. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients.
Weber DC; Johanson S; Peguret N; Cozzi L; Olsen DR
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):490-7. PubMed ID: 20800383
[TBL] [Abstract][Full Text] [Related]
8. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Specht L; Yahalom J; Illidge T; Berthelsen AK; Constine LS; Eich HT; Girinsky T; Hoppe RT; Mauch P; Mikhaeel NG; Ng A;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):854-62. PubMed ID: 23790512
[TBL] [Abstract][Full Text] [Related]
9. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy.
Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck Af Rosenschöld P; Petersen PM; Specht L
Radiother Oncol; 2014 Mar; 110(3):441-7. PubMed ID: 24188865
[TBL] [Abstract][Full Text] [Related]
10. Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment?
Maraldo MV; Brodin P; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):297-303. PubMed ID: 23910709
[TBL] [Abstract][Full Text] [Related]
11. Importance of PET/CT scan use in planning radiation therapy for lymphoma.
Milana MA; Marko E; Miroslav L; Tihomir D
Asian Pac J Cancer Prev; 2015; 16(5):2051-4. PubMed ID: 25773849
[TBL] [Abstract][Full Text] [Related]
12. Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma.
Verhappen MH; Poortmans PM; Raaijmakers E; Raemaekers JM
Radiother Oncol; 2013 Oct; 109(1):133-9. PubMed ID: 24021344
[TBL] [Abstract][Full Text] [Related]
13. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
Hoppe BS; Flampouri S; Su Z; Morris CG; Latif N; Dang NH; Lynch J; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):260-7. PubMed ID: 22014950
[TBL] [Abstract][Full Text] [Related]
14. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy.
Campbell BA; Connors JM; Gascoyne RD; Morris WJ; Pickles T; Sehn LH
Cancer; 2012 Sep; 118(17):4156-65. PubMed ID: 22252721
[TBL] [Abstract][Full Text] [Related]
15. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
Maraldo MV; Brodin NP; Aznar MC; Vogelius IR; Munck af Rosenschöld P; Petersen PM; Specht L
Ann Oncol; 2013 Aug; 24(8):2113-8. PubMed ID: 23619032
[TBL] [Abstract][Full Text] [Related]
16. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open?
Lohr F; Georg D; Cozzi L; Eich HT; Weber DC; Koeck J; Knäusl B; Dieckmann K; Abo-Madyan Y; Fiandra C; Mueller RP; Engert A; Ricardi U
Strahlenther Onkol; 2014 Oct; 190(10):864-6, 868-71. PubMed ID: 25209551
[TBL] [Abstract][Full Text] [Related]
17. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma.
Maraldo MV; Brodin NP; Vogelius IR; Aznar MC; Munck Af Rosenschöld P; Petersen PM; Specht L
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1232-7. PubMed ID: 22270170
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy.
Koeck J; Abo-Madyan Y; Lohr F; Stieler F; Kriz J; Mueller RP; Wenz F; Eich HT
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):268-76. PubMed ID: 22079733
[TBL] [Abstract][Full Text] [Related]
19. Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy.
Filippi AR; Ragona R; Fusella M; Botticella A; Fiandra C; Ricardi U
Pract Radiat Oncol; 2013; 3(3):216-222. PubMed ID: 24674367
[TBL] [Abstract][Full Text] [Related]
20. Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group.
Rosenbrock J; Kaul H; Oertel M; Celik E; Linde P; Fan J; Eichenauer DA; Bröckelmann PJ; von Tresckow B; Kobe C; Dietlein M; Fuchs M; Borchmann P; Eich HT; Baues C
Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38631539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
